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Background: Multimorbidity is common in advanced age, and is usually associated with negative – yet to some
extent preventable – health outcomes. Detecting comorbid conditions is especially difficult in individuals with
dementia, as they might not always be able to sufficiently express discomfort. This study compares relevant
comorbidity complexes in elderly people with and without dementia, with a particular look at gender- and living
environment-specific differences. Moreover, associations between selected comorbid conditions and dementia are
reviewed more closely.
Methods: Using 2006 claims data from a large German Statutory Health Insurance fund, 9,139 individuals with
dementia and 28,614 age- and gender-matched control subjects aged 65 years and older were identified. A total of
30 comorbidity complexes were defined based on ICD-10 codes. Corresponding prevalence rates were calculated,
and the association between a distinct condition and dementia was evaluated via logistic regression in the overall
sample as well as in analyses stratified by gender and living environment.
Results: Individuals with dementia were more likely to be diagnosed with 15 comorbidity complexes, including
Parkinson’s, stroke, diabetes, atherosclerosis (supposed dementia risk factors) or fluids and electrolyte disorders,
insomnia, incontinence, pneumonia, fractures and injuries (supposed sequelae). In contrast, they were less likely to
be diagnosed with 11 other conditions, which included vision and hearing problems, diseases of the
musculoskeletal system, lipoprotein disorders and hypertension. In a gender-stratified analysis, the patterns
remained largely the same, but a bigger comorbidity gap between cases and control subjects emerged in the male
population. Restricting the analysis to community-living individuals did not lead to any substantial changes.
Conclusion: Besides strengthening the evidence on accepted dementia risk factors and sequelae, the analyses
point to particular conditions that are likely to remain untreated or even undiagnosed. This issue seems to affect
male and female individuals with dementia to varying degrees. Raising awareness of these conditions is important
to possibly preventing comorbidity-associated complications and disease progression in dementia patients. To more
comprehensively understand the mutual interactions between dementia and comorbidity, further research on
diagnostic and treatment attitudes regarding comorbidity in dementia patients and on their gender-specific health-
seeking behaviour seems to be required.
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With a growing number of elderly people in Germany, the
occurrence of age-related diseases is increasing steadily.
Dementia is considered to be one of the most challenging
of these, not only for those affected, but also for their rela-
tives and formal caregivers. The term dementia refers to a
collection of symptoms with different underlying causes
that are not yet completely understood. Presumably, patho-
logical changes and lesions involving various brain areas
and neuronal networks lead to changes in the functioning
of the brain, which in consequence affect memory, activities
of daily living (ADL) and the behaviour of patients [1,2].
Multimorbidity is also a well-known phenomenon in the
elderly. According to a recent German study, about 62%
of the population aged 65 years and older is multimorbid
[3]. Yet, findings about whether the amount and type of
comorbidity differ between individuals with and without
dementia are inconclusive. Whereas an older study sug-
gests that Alzheimer patients are healthier [4], some au-
thors find no differences in comorbidity burden [5,6].
Other studies find a higher comorbidity burden in demen-
tia patients [7,8] or report mixed findings, suggesting that
some diseases are more and others less frequent in indi-
viduals with dementia compared with non-demented con-
trol subjects [9,10].
Multimorbidity is associated with a greater risk of dying,
poor functional status, reduced quality of life and greater
use of health care services [11]. It is therefore important
to recognize and manage comorbid conditions well, so
that they do not worsen a person’s health status. Dementia
patients, in particular in the advanced stages, may have
difficulty in communicating their symptoms. In addition,
if dealing with a severe health problem such as dementia,
physicians might lose sight of other conditions. In con-
sequence, dementia patients could be at risk of being
underdiagnosed for comorbid diseases. This hypothesis is
confirmed by Löppönnen et al., who found more undiag-
nosed diseases in patients with dementia than in control
subjects [12].
Highlighting relevant comorbidity in dementia patients
will help to alert physicians and, consequently, to improve
the prevention and treatment of complications in a patient
group that might not always be able sufficiently to express
discomfort. It is also important to take a closer look at the
reasons for observed comorbidity differences. Different
prevalence rates of diagnosed comorbidity might be ex-
plained to some extent by a (dementia-related) change in
pathophysiological mechanisms, which eventually results
in different risks of individuals with and without dementia
for developing a distinct comorbid condition. In this case,
different prevalence rates of documented comorbidity re-
flect a really existing – and medically reasonable – differ-
ence regarding the occurrence of a comorbid condition.
However, differences in documented prevalence mightalso be explained to some extent by different health care-
seeking behaviour or a different attitude towards health
care service provision for individuals with and without
dementia, and hence more likely reflect under-diagnosis
and under-treatment of conditions with a comparable real
prevalence rate.
Cross-sectional population-based studies can be consid-
ered as some kind of gold standard to assess the prevalence
of comorbidity in individuals with and without dementia
as they include a representative sample of individuals at
risk. However, this comprehensive research approach is
rarely chosen [12]. Instead, most previous studies drew
conclusions on comorbidity in individuals with demen-
tia based on hospital admission and discharge data
[4,5,7,9,10], which does not reflect true prevalence rates,
owing to the fact that only a small proportion of all pa-
tients undergoes hospital treatment. To this end, insur-
ance claims data, which include all individuals who seek
any kind of inpatient or outpatient treatment [6,8], seem
to be a less selective approach, as less severe treatment
episodes (which do not require hospitalization) are also
accounted for.
Therefore, we decided to use claims data from a large
regional German Statutory Health Insurance (SHI) fund
to: (1) investigate the prevalence of various diagnosed
comorbidity complexes in dementia patients compared
with control subjects; (2) explore whether the comorbid-
ity pattern changes in a gender-specific analysis; and (3)
identify differences according to living environment.
Methods
Data source and sample selection
Analyses are based on claims data from AOK Bavaria, a
large regional German SHI fund, which covers about 50%
of the resident population aged 65 years and older in the
study region. Complete data from 2005 to 2007 were pro-
vided for all insurants born before 1941 and continuously
insured until 2007.
Dementia cases were identified from 2005 and 2006 data
via in- and outpatient diagnoses and anti-dementia drug
prescriptions. As in the German SHI system physician
diagnoses always refer to a distinct quarter of the year,
each quarter of the years 2005 and 2006 was screened for
the documentation of dementia-specific diagnoses (ICD-
10 codes ‘F00’, ‘F01’, ‘F02’, ‘F03’ and ‘G30’) or anti-dementia
drugs ((ATC codes N06DA (cholinesterase inhibitors) and
N06DX01 (memantine)). To improve the validity of diag-
noses, the analyses accounted only for those individuals
who had at least one corresponding dementia indica-
tor during three out of four consecutive quarters. Non-
demented control subjects were randomly selected from
the remaining insurants without any dementia indicator in
2005 and 2006. They were matched by age based on year
of birth and gender in a 4:1 ratio, with a slightly inexact
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high dementia prevalence in these age groups. Following
this approach, 9,147 dementia patients and 29,741 control
subjects were identified. A detailed description of the se-
lection process can be found elsewhere [13].
Our analyses rely on 2006 data. As prevalent comorbid-
ity is the focus of our analyses, we only included individ-
uals with at least one documented ICD-10 comorbidity
code in 2006, and 9,139 dementia cases (99.9%) and 28,614
control subjects (96.2%) remained.
For the living environment-specific analysis, the insti-
tutional and the community setting were distinguished
based on payments for a component of long-term care in-
surance (LTCI) called ‘institutional care’, which is the only
parameter within German claims data to indicate an indi-
vidual’s care setting. This service domain is only available
for individuals who are institutionalized within nursing
homes or the special wards of residential homes for the
elderly. Assuming that institutional care is only affordable
with LTCI coverage, individuals receiving no LTCI support
at all or no LTCI support for ‘institutional care’ fall into
the community setting. Subjects with an uninterrupted se-
quence of LTCI support for ‘institutional care’ in 2006
were allocated to the institutional setting, and subjects for
whom the starting date of payments for institutional care
was in 2006 were classified as transferring to a nursing
home. Details about the allocation to settings are available
elsewhere [14]. After excluding institutionalized individ-
uals as well as transferring individuals, 5,524 cases and
27,595 control subjects were suitable for the community-
setting analysis. However, our approach does not allocate
residents of homes for the handicapped to the institutional
setting.
Need for care within the different settings is described
by ‘care levels’, which indicate nursing dependency. Three
levels are distinguished that define how often and for how
long assistance with ADL is needed [15]. People with the
highest nursing dependency are assigned to level 3, and
need for care decreases with each level.
Diagnosis groups
We analysed the prevalence of comorbid conditions
based on 2006 inpatient and outpatient diagnoses, which
were grouped into 30 comorbidity complexes.
The choice of comorbidity complexes is based on a list
of 46 chronic conditions compiled by Schäfer et al. [16],
who provide a broad range of chronic disease groups. Be-
cause we also wanted to cover the non-chronic but acute
presence of these conditions (e.g. N17: acute renal failure),
Schäfer’s groups were amended with the respective ICD-
10 codes. Additionally, single ICD-10 codes disregarded
by Schäfer et al., but highly prevalent (prevalence >10%) in
our sample, were assessed. Some of these were added to
existing complexes, and some formed new complexes andwere added to the list of conditions, as well as some
groups that were added after a review of disease groups
commonly chosen by other authors [5-10,12,16-23]. As a
result, 52 comorbidity complexes were assembled and
reviewed.
For our analyses, we included all complexes that had (1)
a prevalence of at least 15% within the case or control
group of our study population or were (2) accounted for
within at least five of the reference studies [5-10,12,16-23]
or were (3) considered as being of significant medical
interest within a thorough appraisal by the authors. Mul-
tiple mentioning of conditions was allowed (e.g. highly
prevalent, and frequently mentioned in previous studies).
Using this approach, 30 comorbidity complexes were fi-
nally considered. The source of origin of these 30 comor-
bidity complexes is accessible as Additional file 1.
For the main analysis, a person was allocated to a
diagnosis group if a corresponding diagnosis was docu-
mented at least once in 2006 in order to capture acute
conditions as well. Additionally, sensitivity analyses with
more restrictive diagnosis documentation requirements
(coding of a diagnosis in at least two or four quarters of
2006) were run.
The overall burden of comorbidity was measured by
the Charlson Index (CI) using the ICD-10 comorbidity
coding algorithm from Quan et al. [24]. The higher the
index, the higher the comorbidity burden. The original
version of the CI includes 17 disease categories with de-
mentia being one of them. Thus, dementia patients with
an equal comorbidity profile to non-demented control
subjects would have a higher CI because dementia con-
tributes to calculating the index score. To reflect disease
burden apart from dementia, we calculated a modified
version of the CI, which consists of only 16 disease cat-
egories and does not include dementia in calculating the
index score.Statistical analysis
Descriptive statistics characterize the study population.
The proportion of affected dementia patients and control
subjects was calculated for each comorbidity complex. To
investigate the association between a comorbidity complex
and dementia, the likelihood of being affected by a comor-
bidity complex in the presence of dementia in comparison
with a control subject was calculated using binary logistic
regression. Because of the mentioned inexact matching
and distortion as a result of restriction of the sample to
people with at least one documented ICD-10 code in
2006, the analysis was adjusted for age and gender.
Odds ratios (ORs), 95% confidence intervals (CI) and p-
values are provided. As we tested 30 comorbidity complexes,
we addressed multiple testing by setting a Bonferroni-
adjusted significance level of p < 0.0017 (0.05/30).
Bauer et al. BMC Geriatrics 2014, 14:10 Page 4 of 13
http://www.biomedcentral.com/1471-2318/14/10To evaluate the impact of gender, a dementia–gender
interaction term was added to the model and, as the inter-
action terms were significant for the majority of comor-
bidity complexes, we also chose to display the results of a
gender-stratified analysis, which is adjusted for age only.




The study population included 37,753 individuals aged
between 65 and 103 years. Some 27,012 (71.6%) individ-
uals were female, and 33,119 individuals (87.7%) lived
within the community setting during the entire observa-
tion period.
Table 1 displays the demographic characteristics of
the study population as a whole as well as according to
dementia status. Comparing individuals with and with-
out dementia revealed that the share of permanently
community-living individuals was significantly higher in
non-demented control subjects (96.4% vs. 67.9%). Corre-
sponding to this, 88.3% of control subjects showed no im-
pairment in ADL (no care level), whereas only 37.9%
of dementia patients hardly needed assistance at all (p
<0.0001). The modified CI was significantly higher in the
case group (p <0.0001) and significantly higher for men
than for women in both groups (p <0.0001 each).
Range of comorbidity
Table 2 displays the comorbidity complexes. In both, the
case and the control group, hypertension was the most
common comorbidity complex: it was documented for
73.4% of dementia patients and 77.8% of control subjects.Table 1 Baseline characteristics of 2006 study sample
Entire sample
Number: N 37,753
Age: mean (SD) 80.1 (6.8)
Gender: females (%) 27,012 (71.6)
Environment: n (%)
Living in community setting 33,119 (87.7)
Living in nursing home 3,646 (9.7)
Change in environment 988 (2.6)





Modified Charlson Index**: mean (SD) 3.2 (2.7)
SD = Standard Deviation. *Care level corresponds to the care level on 30 June 2006
**The Charlson Index (CI) category ‘dementia’ is set at zero for all individuals.
***P-values derived from Chi2 test for distinct variables and from Kruskal–Wallis testHypertension was followed by lower back pain in the con-
trol group (58.9%) and incontinence (50.3%) in the case
group. The prevalence of disorders directly related to de-
mentia development (Parkinson’s, stroke) was increased for
dementia patients, as well as the prevalence of diseases that
are related to loss of cognitive abilities (incontinence, elec-
trolyte and fluid imbalances). Also, fractures and injuries,
pneumonia, mental and behavioural disorders, anaemia,
diabetes as well as cardiac and renal insufficiency were ob-
served more often in dementia patients. In contrast, prob-
lems with the musculoskeletal system, vision and hearing
were documented less frequently for cases. Cancer, thyroid
dysfunction, lipoprotein disorders, hypertension, arrhyth-
mias and varicosis were also less frequent in cases than
in control subjects. This is reflected in the results of the
logistic regression, with high ORs for Parkinson’s disease
(5.21), incontinence (3.01), cerebral ischaemia/chronic
stroke (2.59), pneumonia (2.31) and depression (2.08) and
low ORs for vision reduction (0.59), lower back pain (0.69),
lipoprotein disorders (0.72), joint arthrosis (0.74) and
hypertension (0.76). The sensitivity analyses did not show
substantial changes in the results for most of the groups;
in particular, there were no substantial changes in ORs.
Gender-stratified case–control comparison
As pointed out in Table 3, females with and without de-
mentia were older than their male counterparts (p <0.0001
for both) and, in both groups, fewer women than men
stayed in the community setting (p <0.0001 for both).
Table 4 displays gender-specific comorbidity. Consider-
ing the Bonferroni adjustment, the dementia–gender inter-
action terms added to the first model were significant for
14 of the 30 comorbidity complexes (thyroid dysfunction,Case group Control group p-value***
9,139 28,614
81.6 (7.4) 79.6 (6.4) <0.0001
6,814 (74.6) 20,198 (70.6)
<0.0001
5,524 (60.4) 27,595 (96.4) <0.0001
2,934 (32.1) 712 (2.5)
681 (10.3) 307 (1.1)
<0.0001
3,466 (37.9) 25,280 (88.3)
2,066 (22.6) 2,140 (7.5)
2,164 (23.7) 967 (3.4)
1,443 (15.8) 227 (0.8)
3.6 (2.7) 3.0 (2.7) <0.0001
.
for continuous variables.
Table 2 Diagnosed comorbidity complexes of dementia patients and control subjects








Cancer (all) (C00–D48) 2,284 (25.0) 7,880 (27.5) 0.89 (0.85–0.94) <0.0001
Diseases of the blood and blood-forming organs
Anaemia (D50–53, D55–64) 2,321 (25.4) 5,518 (19.3) 1.40 (1.32–1.48) <0.0001
Endocrine, nutritional and metabolic diseases
Thyroid dysfunction (E01–07) 2,266 (24.8) 8,027 (28.1) 0.86 (0.81–0.91) <0.0001
Diabetes (E10–14) 4,135 (45.2) 11,252 (39.3) 1.29 (1.23–1.35) <0.0001
Disorders of lipoprotein metabolism and other lipidaemias (E78) 3,797 (41.5) 14,685 (51.3) 0.72 (0.69–0.76) <0.0001
Fluids/electrolyte disorders (E86, E87, R60) 3,175 (34.7) 5,712 (20.0) 2.01 (1.91–2.12) <0.0001
Mental and behavioural disorders
Psychotic/neurotic disorders (F20–29, F40–48) 2,189 (24.0) 5,122 (17.9) 1.53 (1.45–1.62) <0.0001
Depression (F32–33) 2,790 (30.5) 5,017 (17.5) 2.08 (1.97–2.20) <0.0001
Insomnia (F51, G47) 1,485 (16.2) 3,504 (12.2) 1.34 (1.26–1.43) <0.0001
Diseases of the nervous system
Parkinson’s disease (G20–22) 1,203 (13.2) 805 (2.8) 5.21 (4.75–5.72) <0.0001
Diseases of the eye and ear
Severe vision reduction (H17–18, H25–28, H31, H33, H34.1–34.2,
H34.8–34.9, H35–36, H40, H43, H47, H54)
3,406 (37.3) 14,254 (49.8) 0.59 (0.57–0.62) <0.0001
Severe hearing loss (H90, H91) 1,650 (18.1) 5,267 (18.4) 0.91 (0.86–0.97) 0.004
Diseases of the circulatory system
Hypertension (I10–15) 6,704 (73.4) 22,266 (77.8) 0.76 (0.72–0.80) <0.0001
Coronary artery disease (CAD) (I20–25) 3,638 (39.8) 11,018 (38.5) 1.01 (0.96–1.06) 0.821
Cardiac arrhythmias (I44–49) 2,570 (28.1) 8,229 (28.8) 0.92 (0.87–0.97) 0.002
Cardiac insufficiency (I50) 4,233 (46.3) 9,277 (32.4) 1.58 (1.50–1.66) <0.0001
Atherosclerosis/peripheral arterial occlusive disease (I65–66, I67.2, I70, I73.9) 3,945 (43.2) 8,838 (30.9) 1.64 (1.56–1.72) <0.0001
Cerebral ischaemia/chronic stroke (G45, I60–64, I69) 2,960 (32.4) 4,352 (15.2) 2.59 (2.45–2.74) <0.0001
Lower limb varicosis (I83, I87.2) 2,093 (22.9) 7,316 (25.6) 0.85 (0.80–0.89) <0.0001
Diseases of the respiratory system
Pneumonia (J12–18) 1,062 (11.6) 1,497 (5.2) 2.31 (2.12–2.51) <0.0001
Asthma/chronic obstructive pulmonary disease (COPD) (J40–47) 2,403 (26.3) 7,273 (25.4) 1.05 (1.00–1.11) 0.060
Diseases of the musculoskeletal system and connective tissue
Arthritis (M02, M05–06, M08, M10, M11–13) 1,035 (11.3) 3,932 (13.7) 0.82 (0.76–0.88) <0.0001
Joint arthrosis (M15–19) 3,746 (41.0) 13,524 (47.3) 0.74 (0.71–0.78) <0.0001
Purine/pyrimidine metabolism disorders/gout (E79, M10) 2,291 (25.1) 8,141 (28.5) 0.86 (0.82–0.91) <0.0001
Lower back pain (M40–48, M50–54) 4,474 (49.0) 16,857 (58.9) 0.69 (0.66–0.72) <0.0001
Osteoporosis (M80–82) 2,178 (23.8) 6,465 (22.6) 1.00 (0.95–1.06) 0.937
Diseases of the genitourinary system
Renal insufficiency/failure (N17–19) 1,978 (21.6) 4,667 (16.3) 1.36 (1.28–1.44) <0.0001
Incontinence (N39.3, R32, R15) 4,594 (50.3) 6,914 (24.2) 3.01 (2.87–3.17) <0.0001
Fractures, injuries and fall risks
Fractures and injuries (S00–T14) 3,965 (43.4) 8,958 (31.3) 1.60 (1.52–1.68) <0.0001
Fall risk and dizziness (R26, R29.6, R42, H81, H82) 2,251 (24.6) 5,761 (20.1) 1.23 (1.16–1.30) <0.0001
*ORs are adjusted for age and sex.
**Bold p-values considered significant according to Bonferroni adjustment.
Bauer et al. BMC Geriatrics 2014, 14:10 Page 5 of 13
http://www.biomedcentral.com/1471-2318/14/10
Table 3 Gender-specific baseline characteristics of 2006 study sample
Male Female
Characteristics All Case Control p-value*** All Case Control p-value***
Number: N 10,741 2,325 8,416 27,012 6,814 20,198
Age: mean (SD) 77.7 (6.7) 78.2 (7.2) 77.5 (6.6) <0.0001 81.0 (6.5) 82.8 (7.2) 80.4 (6.2) 0.0009
Environment: n (%) <0.0001 <0.0001
Living in community setting 9,973 (92.8) 1,684 (72.4) 8,289 (98.5) 23,146 (85.7) 3,840 (56.4) 19,306 (95.6)
Living in nursing home 562 (5.2) 482 (20.7) 80 (1.0) 3,084 (11.4) 2,452 (36.0) 632 (3.1)
Change in environment 206 (1.9) 159 (6.8) 47 (0.6) 782 (2.9) 522 (7.7) 260 (1.3)
Care level*: n (%) <0.0001 <0.0001
None 8,823 (82.1) 1,047 (45.0) 7,776 (92.4) 19,923 (73.8) 2,419 (35.5) 17,504 (86.7)
1 926 (8.6) 518 (22.3) 408 (4.8) 3,280 (12.1) 1,548 (22.7) 1,732 (8.6)
2 708 (6.6) 512 (22.0) 196 (2.3) 2,423 (9.0) 1,652 (24.2) 771 (3.8)
3 284 (2.6) 248 (10.7) 36 (0.4) 1,386 (5.1) 1,195 (17.5) 191 (0.9)
CI**: mean (SD) 3.7 (3.0) 4.3 (3.0) 3.5 (3.0) <0.0001 3.0 (2.5) 3.4 (2.5) 2.8 (2.5) <0.0001
SD = Standard Deviation. *Care level corresponds to the care level on 30 June 2006.
**The Charlson Index (CI) category ‘dementia’ is set at zero for all individuals.
***P-values derived from Chi2 test for distinct variables and from Kruskal–Wallis test for continuous variables.
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hypertension, cardiac insufficiency, atherosclerosis/periph-
eral arterial occlusive diseases, cerebral ischaemia/stroke,
lower limb varicosis, joint arthrosis, osteoporosis, incontin-
ence as well as fall risks/dizziness). The tendency of the
ORs remained largely constant in both male and female co-
horts. When comparing the likelihood of a male dementia
patient being diagnosed with a certain comorbidity com-
plex (compared with a control subject) with the likelihood
of a female dementia patient for the same complex, the OR
of the male cohort almost always exceeded the correspond-
ing OR in the female cohort. For instance, large differences
were observed for Parkinson’s (6.64 male vs. 4.71 female),
incontinence (4.19 male vs. 2.71 female), stroke (3.32 male
vs. 2.34 female), depression (2.81 male vs. 1.93 female) and
vision reduction (0.73 male vs. 0.56 female).
Community setting
After restricting the main analysis to people living in a
community setting (Table 5), prevalence rates in the
control group hardly changed, as 96.4% of the control
population were living in the community setting anyway.
For the dementia population, the largest prevalence de-
crease was observed for incontinence and fluids/electro-
lyte disorders and the largest increase for back pain and
lipoprotein disorders. In the community setting, the like-
lihood of a dementia patient being diagnosed with a co-
morbidity complex was higher than in the main analysis,
except for Parkinson’s, pneumonia, incontinence, fluids/
electrolyte disorders, fractures and injuries, stroke and
cardiac insufficiency.
A gender-stratified analysis of the community-living po-
pulation revealed a particularly strong decrease in ORsregarding the first five of these comorbidity complexes for
both genders and a particularly strong increase in ORs re-
garding lower back pain, dyslipidaemia, fall risks/dizziness
and lower limb varicosis. Altogether, the percentage change
in ORs was in general more pronounced in women than in
men. Further information on this gender-stratified analysis
is available as Additional file 2.
Discussion
Based on insurance claims data, we examined the docu-
mented prevalence of comorbid conditions in people with
dementia and a control population. In the overall sample,
people with dementia had a significantly higher chance
than control subjects of being diagnosed with a certain co-
morbid condition for 15 out of 30 investigated comorbid-
ity complexes and a significantly lower chance for 11 of
them. In comparison with the control subjects, men with
dementia seemed to be affected more frequently than
women with dementia for distinct conditions. Restricting
the analysis to people living in the community setting did
not lead to crucial changes in the results.
To comprehensively judge our findings, different ex-
planatory approaches regarding the observed prevalence
rates of documented comorbidity have to be considered.
First, the observed associations could be based on com-
mon pathology. There are conditions, in particular
Parkinson’s disease [25], stroke [2,26,27], vascular risk fac-
tors such as diabetes, atherosclerosis and hypertension
[28-32] and possibly depression [33,34], that are estab-
lished risk factors for dementia. Except for hypertension,
the chance of being affected by these comorbidity com-
plexes was higher for dementia patients in our study as
well. Our finding of an inverse association between
Table 4 Diagnosed comorbidity complexes of dementia patients and control subjects stratified by gender
Men (N = 10,741; 2,325 cases;
8,416 control subjects)












Cancer (all) 33.9 35.9 0.90 (0.82–0.99) 22.0 24.1 0.91 (0.85–0.97) 0.589
Diseases of the blood and blood-forming organs
Anaemia 26.1 20.0 1.40 (1.26–1.56) 25.2 19.0 1.40 (1.31–1.50) 0.925
Endocrine, nutritional and metabolic diseases
Thyroid dysfunction 18.0 17.7 1.02 (0.91–1.16) 27.1 32.4 0.83 (0.78–0.88) <0.0001
Diabetes 47.9 40.2 1.38 (1.26–1.51) 44.3 39.0 1.25 (1.18–1.32) 0.109
Disorders of lipoprotein metabolism and other lipidaemias 45.1 51.0 0.81 (0.74–0.89) 40.3 51.5 0.70 (0.66–0.74) 0.008
Fluids/electrolyte disorders 32.2 17.2 2.24 (2.02–2.49) 35.6 21.1 1.94 (1.83–2.06) 0.016
Mental and behavioural disorders
Psychotic/neurotic disorders 20.5 13.5 1.67 (1.48–1.88) 25.1 19.7 1.51 (1.42–1.62) 0.054
Depression 24.5 10.4 2.81 (2.50–3.17) 32.6 20.5 1.93 (1.81–2.05) <0.0001
Insomnia 14.9 9.6 1.65 (1.44–1.88) 16.7 13.3 1.25 (1.16–1.35) <0.0001
Diseases of the nervous system
Parkinson’s disease 17.0 2.9 6.64 (5.62–7.84) 11.9 2.8 4.71 (4.21–5.28) <0.0001
Diseases of the eye and ear
Severe vision reduction 39.8 47.2 0.73 (0.67–0.80) 36.4 50.9 0.56 (0.53–0.59) <0.0001
Severe hearing loss 20.9 20.8 0.97 (0.87–1.09) 17.1 17.4 0.90 (0.83–0.97) 0.172
Diseases of the circulatory system
Hypertension 71.6 73.2 0.92 (0.83–1.02) 74.0 79.8 0.70 (0.66–0.75) <0.0001
Coronary artery disease (CAD) 45.6 42.9 1.10 (1.00–1.20) 37.8 36.7 0.97 (0.91–1.02) 0.044
Cardiac arrhythmias 33.9 31.6 1.03 (0.94–1.14) 26.5 27.6 0.88 (0.83–0.94) 0.003
Cardiac insufficiency 40.9 26.2 1.90 (1.73–2.10) 48.2 35.0 1.48 (1.39–1.56) <0.0001
Atherosclerosis/peripheral arterial occlusive disease 47.7 32.6 1.86 (1.70–2.05) 41.6 30.2 1.56 (1.48–1.66) 0.002
Cerebral ischaemia/chronic stroke 39.1 16.1 3.32 (3.00–3.67) 30.1 15.9 2.34 (2.19–2.50) <0.0001
Lower limb varicosis 17.2 16.6 1.04 (0.92-1.17) 24.8 29.3 0.81 (0.76-0.86) <0.0001
Diseases of the respiratory system
Pneumonia 14.6 6.4 2.45 (2.12–2.83) 10.6 4.7 2.23 (2.02–2.48) 0.353
Asthma/chronic obstructive pulmonary disease (COPD) 34.2 31.0 1.15 (1.04–1.27) 23.6 23.1 1.02 (0.95–1.09) 0.030
Diseases of the musculoskeletal system and connective tissue
Arthritis 13.4 15.3 0.86 (0.76–0.99) 10.6 13.1 0.79 (0.73–0.87) 0.348
Joint arthrosis 36.0 39.6 0.85 (0.77–0.93) 42.7 50.5 0.71 (0.68–0.76) 0.001
Purine/pyrimidine metabolism disorders/gout 32.9 36.8 0.85 (0.77–0.93) 22.4 25.0 0.86 (0.81–0.92) 0.581
Lower back pain 48.5 55.7 0.76 (0.69–0.83) 49.1 60.3 0.67 (0.63–0.71) 0.016
Osteoporosis 8.6 6.5 1.33 (1.12–1.57) 29.0 29.3 0.97 (0.91–1.03) <0.0001
Diseases of the genitourinary system
Renal insufficiency/failure 28.3 20.5 1.50 (1.35–1.66) 19.4 14.6 1.30 (1.21–1.40) 0.024
Incontinence 48.3 18.2 4.19 (3.79–4.63) 50.9 26.7 2.71 (2.56–2.87) <0.0001
Injuries, fractures and fall risks
Fractures and injuries 37.3 27.8 1.52 (1.38–1.68) 45.5 32.8 1.63 (1.54–1.73) 0.253
Fall risk and dizziness 22.8 15.4 1.59 (1.42–1.78) 25.2 22.1 1.14 (1.07–1.22) <0.0001
*ORs are adjusted for age.
**P-values for case*gender interaction, when interaction term was added to the model in Table 2; bold p-values considered significant according to Bonferroni adjustment.
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portance of age at hypertension exposure: midlife blood
pressure is eventually the more relevant predictor of de-
mentia development compared with hypertension in later
life [28,31]. The decline in blood pressure in later life might
be secondary to the brain lesions [31,35] and may give the
impression of a ‘normalization’ of blood pressure values
during the course of dementia progression [35], which
might contribute to a lower prevalence of documented
hypertension in individuals with dementia. This alternative
explanatory approach is supported by our finding that the
gap between dementia patients and non-demented control
subjects is reduced when only community-living individ-
uals are examined (OR = 0.90 vs. OR = 0.76) and nursing
home residents – who are older and most probably at a
more advanced stage of dementia – are disregarded.
Some other conditions are likely to be dementia sequelae.
These include the inadequate intake of water and electro-
lytes [36,37], incontinence [38] and aspiration pneumonia
in late-stage dementia [39,40]. Increased odds for pneu-
monia can also be attributed to the higher proportion of
Parkinson patients among the dementia population, who
are susceptible to aspiration pneumonia as well. Further-
more, neurodegenerative changes in the brain probably
affect sleep regulation [41,42], as well as disorganization of
the network that controls locomotion, leading to impaired
gait timing and postural control [43]. This is one explan-
ation for a difference in fall and fracture rates.
Yet, most of the comorbidity complexes inversely associ-
ated with dementia in our study have not been investi-
gated very often. Sources of bias together with the lack of
data result in contradictory findings and make it hard to
explain the inverse connections. An exception might be
diseases of the musculoskeletal system and connective tis-
sue. They usually manifest in pain, and thus could be
negatively associated with dementia because of altered
pain processing [44]. The inappropriate communication of
pain is another likely reason that may contribute to the
negative association. With progressing dementia, the cap-
abilities of expressing and especially verbalizing pain de-
crease step by step. Thus, individuals with dementia might
face difficulties in raising awareness of their physical pain.
Deficits in communication also seem to be a possible ex-
planation for the lower prevalence of diagnosed vision and
hearing impairment in individuals with dementia.
Second, the observed associations could be based on dif-
fering utilization patterns of individuals with and without
dementia. Only if a patient presents to a physician will
his/her diagnoses be reflected in claims data. A recent
German study found that incident dementia leads to an
increase in service utilization, as well as that the majority
of dementia patients’ physician contacts (79%) take place
in the disciplines of primary care and neuropsychiatry
[45]. Other studies report that the number of differentphysicians contacted seems to be rather low for multimor-
bidity patterns including dementia as well [46], and that,
in comparison with a control population, a larger propor-
tion of dementia patients presents to a general practi-
tioner, but a smaller proportion to specialists (neurologists
and psychiatrists excluded) [47]. This applies especially to
ophthalmologists, gynaecologists, otolaryngologists, cardi-
ologists and orthopaedists, who are all specialists in dis-
ease groups that are mainly inversely associated with
dementia in our study. If the fewer visits do not in fact
correspond with fewer health problems in these specialty
areas, the amount of comorbidity experienced by demen-
tia patients in these groups is underestimated. General
practitioners should consider more carefully when referral
of a dementia patient to a specialist is necessary.
The third aspect is closely related to the second one.
Documented morbidity does not always match actual mor-
bidity. When Löppönnen et al. [12] compared recorded
diseases with an additional clinical examination they found
that more dementia patients than control subjects were ac-
tually underdiagnosed. This seems perfectly reasonable as
demented individuals probably have greater difficulty in
communicating their symptoms and, in the presence of a
severe health problem such as dementia, physicians might
overlook or simply ignore less severe diseases. Moreover,
physicians might come to the conscious decision not to
treat these comorbidity complexes based on the assump-
tion that therapeutic interventions for these not per se
life-threatening conditions reduce the dementia patients’
remaining quality of life disproportionately compared with
the beneficial effects of treatment. However, some kind of
therapeutic nihilism that therapy of these comorbidity
complexes in conformity with guidelines is less worthwhile
in a cognitively impaired population also cannot be fully
excluded. The lower rate of vision and hearing problems,
arrhythmias, hypertension, varicosis and musculoskeletal
diseases in our study matches this hypothesis.
In this context, some comorbidity complexes stand out
from our analysis. Hypertension is the most surprising ex-
ample of a lower documented prevalence rate, as one
would expect at least similar occurrence of hypertension
in the case and control group. We have already provided
possible explanations in a previous paragraph, yet those
are unconfirmed hypotheses. Therefore, we also want to
bring up potential under-diagnosis of hypertension. We
highlight hypertension as it is a risk factor for a number of
other conditions such as stroke or cardiovascular disease,
and preventing these complications will certainly influence
the patients’ quality of life.
Supposedly better vision and hearing in people with
dementia also seems implausible. Diagnosing diseases of
the eye and ear usually requires the patients’ participa-
tion, and the process is more difficult and exhausting
when dealing with a dementia patient. In consideration
Table 5 Diagnosed comorbidity complexes of community-living dementia patients and control subjects
Diagnosis group n (%) case N = 5,524 n (%) control N = 27,595 OR* (CI) p-value**
Neoplasms
Cancer (all) 1,514 (27.4) 7,637 (27.7) 0.98 (0.92–1.05) 0.600
Diseases of the blood and blood-forming organs
Anaemia 1,383 (25.0) 5,271 (19.1) 1.40 (1.31–1.50) <0.0001
Endocrine, nutritional and metabolic diseases
Thyroid dysfunction 1,492 (27.0) 7,766 (28.1) 0.96 (0.90–1.03) 0.251
Diabetes 2,534 (45.9) 10,766 (39.0) 1.33 (1.25–1.41) <0.0001
Disorders of lipoprotein metabolism and other lipidaemias 2,667 (48.3) 14,320 (51.9) 0.89 (0.84–0.94) <0.0001
Fluids/electrolyte disorders 1,615 (29.3) 5,315 (19.3) 1.70 (1.60–1.82) <0.0001
Mental and behavioural disorders
Psychotic/neurotic disorders 1,403 (25.4) 4,933 (17.9) 1.62 (1.51–1.73) <0.0001
Depression 1,736 (31.4) 4,708 (17.1) 2.28 (2.14–2.44) <0.0001
Insomnia 928 (16.8) 3,302 (12.0) 1.47 (1.36–1.60) <0.0001
Diseases of the nervous system
Parkinson’s disease 558 (10.1) 704 (2.6) 4.25 (3.78–4.77) <0.0001
Diseases of the eye and ear
Severe vision reduction 2,318 (42.0) 13,826 (50.1) 0.72 (0.68–0.76) <0.0001
Severe hearing loss 1,096 (29.8) 5,057 (18.3) 1.07 (0.99–1.15) 0.076
Diseases of the circulatory system
Hypertension 4,197 (76.0) 21,455 (77.7) 0.90 (0.84–0.96) 0.002
Coronary artery disease (CAD) 2,285 (41.4) 10,584 (38.4) 1.11 (1.04–1.17) <0.0001
Cardiac arrhythmias 1,685 (30.5) 7,908 (28.7) 1.06 (1.00–1.13) 0.061
Cardiac insufficiency 2,350 (42.5 8,692 (31.5) 1.56 (1.47–1.66) <0.0001
Atherosclerosis/peripheral arterial occlusive disease 2,494 (45.1) 8,425 (30.5) 1.85 (1.74–1.96) <0.0001
Cerebral ischaemia/chronic stroke 1,651 (29.9) 3,963 (14.4) 2.51 (2.34–2.68) <0.0001
Lower limb varicosis 1,462 (26.5) 7,056 (25.6) 1.05 (0.98–1.12) 0.143
Diseases of the respiratory system
Pneumonia 482 (8.7) 1,375 (5.0) 1.80 (1.61–2.00) <0.0001
Asthma/chronic obstructive pulmonary disease (COPD) 1,472 (26.6) 6,989 (25.3) 1.07 (1.00–1.14) 0.056
Diseases of the musculoskeletal system and connective tissue
Arthritis 712 (12.9) 3,793 (13.7) 0.93 (0.85–1.01) 0.102
Joint arthrosis 2,446 (44.3) 13,046 (47.3) 0.88 (0.83–0.93) <0.0001
Purine/pyrimidine metabolism disorders/gout 1,543 (27.9) 7,872 (28.5) 0.97 (0.91–1.03) 0.322
Lower back pain 3,124 (56.6) 16,377 (59.3) 0.90 (0.85–0.96) <0.0001
Osteoporosis 1,365 (24.7) 6,192 (22.4) 1.14 (1.06–1.22) <0.0001
Diseases of the genitourinary system
Renal insufficiency/failure 1,166 (21.1) 4,409 (16.0) 1.37 (1.27–1.48) <0.0001
Incontinence 2,456 (44.5) 6,392 (23.2) 2.64 (2.49–2.81) <0.0001
Injuries, fractures and fall risks
Fractures and injuries 2,122 (38.4) 8,505 (30.8) 1.38 (1.30–1.47) <0.0001
Fall risk and dizziness 1,524 (27.6) 5,519 (20.0) 1.50 (1.40–1.60) <0.0001
*ORs are adjusted for age and sex.
**Bold p-values considered significant according to Bonferroni adjustment.
Bauer et al. BMC Geriatrics 2014, 14:10 Page 9 of 13
http://www.biomedcentral.com/1471-2318/14/10
Bauer et al. BMC Geriatrics 2014, 14:10 Page 10 of 13
http://www.biomedcentral.com/1471-2318/14/10of the extra effort, physicians might discontinue diagno-
sis of these seemingly less severe diseases. However, see-
ing and hearing abilities are important for taking part in
daily life. Additionally, studies from various settings sug-
gest that non-pharmacological, multicomponent inter-
ventions have the potential to slow down the decline in
cognitive function and support the capacity to carry out
Activities of Daily Living [48,49]. Not taking care of vi-
sion and hearing impairment means taking away the de-
mentia patients’ chance of participating properly in these
types of interventions, and thus taking away an oppor-
tunity to slow down the course of the disease.
Comorbidity and gender
Basically, men with and without dementia do not have a
higher comorbidity burden than females with and with-
out dementia, but there is a gender-specific comorbidity
profile. The comorbidity patterns of male and female in-
dividuals observed in our study are similar to patterns
found by other authors who assessed gender-specific
multimorbidity [16,46]. Women both with and without
dementia suffer more frequently from osteoporosis and
thyroid dysfunction as well as from mental health prob-
lems, but less frequently from cancer and cardiovascular
diseases.
Yet, the effect of gender on the case–control compari-
son was striking. When comparing cases and control
subjects for the male and female population separately,
gender did have a significant influence on the ORs for
half the comorbidity complexes. Also, except for four
conditions (fractures/injuries, purine/pyrimidine metab-
olism disorders, cancer and anaemia), the ORs of the
male sample exceeded the corresponding ORs of the fe-
male sample for the respective comorbidity complex.
This implies that the documented prevalence of comor-
bidity complexes is more similar between female cases
and control subjects. For example, women with demen-
tia had an OR of 3.01 of being diagnosed with incon-
tinence, whereas the OR of a male dementia patient of
being diagnosed with incontinence was 4.19. Van den
Bussche et al. [3] also found that, compared with sub-
jects without dementia, men with dementia have a
higher relative risk of multimorbidity than women with
dementia (RR 4.9 vs. 3.4).
To our knowledge, other studies investigating demen-
tia and comorbidity did not focus on gender differences.
This makes our finding even harder to explain. We did
not find sound literature providing explanations for co-
morbidity differences based on the different physiology
of men and women with dementia, but dementia re-
search is far from complete. Hence, the effect of demen-
tia on the development of other medical conditions
might indeed differ for men and women, despite corre-
sponding evidence is lacking.There might also be differences in the diagnosis of co-
morbidity in men and women. We assume that the per-
sonal interaction between male patients and their
physicians differs in comparison with female patients.
One factor might be that the majority of physicians are
males themselves, which might ease talking about sensi-
tive issues. Moreover, symptoms of diseases (e.g. cardiac
infarction) have mainly been deduced from male pa-
tients; thus physicians might be more aware of the
symptom profile in male patients than in female ones.
As an additional factor, one might argue that men might
communicate their interests with more impetus than
women. However, as far as we are able to judge, these
effects apply to men both with and without dementia
and might rather explain different prevalence rates be-
tween men and women than different ORs in the
gender-stratified case–control comparison.
Last, differences in health care service utilization could
also be an explanation. We hypothesize that men only see
the need to visit a physician when a disease becomes
manifest [50], whereas females see more different physi-
cians and report on their health problems more frequently
[45]. This could make the male control subjects look
healthier than they really are. Manifestation of dementia
increases services utilization [45,50] and, consequently,
physicians also document other, previously ignored health
problems in the male population. The fact that male de-
mentia patients probably still live with a spouse who is
vigilant about regular physician’s visits, whereas older
women are more often single-living and have no advocacy
caring for their health care-seeking behaviour very likely
adds to the effect, too.
Comorbidity and living environment
For our analysis of comorbidity in the community set-
ting, nursing home residents were excluded. This prob-
ably implies the exclusion of people with severe disease.
As 42.4% of dementia cases but only 3.6% of control
subjects were in or moved to an institution in 2006, the
restriction concerns mostly advanced-stage dementia pa-
tients, who again carry particular comorbid conditions.
This explains the decrease in ORs for comorbidity com-
plexes that are common in late-stage dementia, such as
pneumonia, incontinence, fluid disorders or fall risks
and also for Parkinson’s disease. The ORs for most other
comorbidity complexes are comparable to the ORs in
the main analysis. Slight differences may be attributed to
frame conditions such as differing medication use or dif-
fering amounts of care and supervision.
Strengths and weaknesses
Using claims data from a German SHI fund for analyses
is associated with some intrinsic challenges, as pointed
out by Schubert et al. [51].
Bauer et al. BMC Geriatrics 2014, 14:10 Page 11 of 13
http://www.biomedcentral.com/1471-2318/14/10First, for historic reasons, the distinct SHI funds cover
different clienteles. Our analyses used data from the
AOK Bavaria SHI fund, which is the market leading
fund in the study region. It is known that the AOK SHI
fund has a comparatively high proportion of insurants
with low income, low educational level and poor health
status [52]. Thus, the observed prevalence rates most
likely overestimate the real prevalence within the entire
population aged 65 years and older. However, it has to
be assumed that the effect of overestimation affects the
various comparison groups in a similar way; thus the pre-
sented ORs seem to be better transferable than the preva-
lence rates themselves.
Another challenge is that documented diagnoses cannot
be validated via clinical examinations; hence their accuracy
remains uncertain. It cannot be fully excluded that physi-
cians misdiagnosed or miscoded some comorbid condi-
tions. To account for this uncertainty, we conducted
sensitivity analyses within which the multiple documenta-
tion of comorbid conditions was required. This more strict
approach towards comorbidity hardly altered the preva-
lence rates compared with the main analysis where a co-
morbid condition needed to be documented only once.
Hence, as per our point of view, miscoding and misclassi-
fication seem not to be a substantial source of bias.
Claims data lack information on disease severity. There-
fore, it was (1) not possible to evaluate whether the severity
level of documented comorbid conditions was comparable
between our study groups and (2) whether different stages
of dementia were associated with specific comorbidity pro-
files. Additionally, differential diagnoses of dementia sub-
types are not made forcefully. In consequence, different
subtypes of dementia are documented insufficiently, and
mostly ‘unspecified dementia’ (ICD-10 code ‘F03’) is re-
ported. Hence, we decided against a stratified analysis for
different subtypes of dementia. Therefore, probable differ-
ences in the comorbidity profile of individuals with vascu-
lar dementia and individuals with a neurodegenerative
form of dementia have been ignored.
Besides these more content-related aspects, it has to
be mentioned that, owing to the large sample size, even
small differences in the documented prevalence of co-
morbidity become statistically significant even though
they might not per se be clinically relevant. We tried to
address this issue by reporting adjusted prevalence rates,
ORs and 95% CIs in addition to p-values in order to
allow a more comprehensive judgment of our findings.
In contrast to these drawbacks, claims data have some
convincing advantages.
First, diagnoses can cover the entire range of existing
ICD-10 codes and are not limited to a restrictive set of
common codes. Therefore, our analyses were able to in-
vestigate the relevance of less common comorbidity com-
plexes that had been neglected in previous studies, such asthe entire range of musculoskeletal disorders, vision and
hearing loss or fall risks.
Second, to assign individuals to comorbidity groups,
hospital diagnoses as well as outpatient diagnoses were
considered. Hence, we believe we have more comprehen-
sively captured the effective patient clientele. In particular,
research assessing comorbidity based on inpatient diagno-
ses [4,5,7,9,10] most probably underestimates true preva-
lence rates because hospital treatment is only sought by a
minority of patients (within our sample: 27.1% of individ-
uals without and 40.2% of individuals with dementia).
Moreover, selection bias is restrained, as claims data-
based samples also include the oldest of the old, frail in-
dividuals and especially institutionalized individuals who
are often not captured in primary data-based studies. As
a consequence, the variance in comorbidity profiles in
different residential settings can be evaluated. To our
knowledge, the effect of care setting on the comorbidity
profile of individuals with and without dementia has so
far not been investigated in a comparably comprehensive
manner as within our own study.
This also applies to the gender-stratified comparison.
The body of evidence on gender-specific comorbidity pro-
files in individuals with dementia is small. In particular, we
found no other studies that investigated a possible inter-
action between the documentation of a comorbid condi-
tion and gender. Our study did, and revealed a significant
influence of male gender on the documentation of many
comorbidity complexes. However, our study describes
some possible explanatory approaches for this observed
phenomenon, but it could not unambiguously provide the
reasons why the comorbidity gap between male cases and
control subjects is more pronounced than that between fe-
male cases and control subjects. This illustrates the need
for further more qualitative research in this regard.Conclusion
Our data confirm known dementia risk factors and se-
quelae that should be managed adequately and in due
time. We also point to conditions that might be prone
to under-diagnosis and lack of treatment, such as hyper-
tension, problems with vision and hearing or musculo-
skeletal disease. Physicians should be especially alert to
these conditions, which seem to be related to complica-
tions, more rapid dementia progression and reduced
quality of life. These comorbidity complexes might rep-
resent a starting point in the development of strategies
to prevent comorbidity-associated negative health out-
comes and to improve care for individuals with dementia.
To further identify undiagnosed comorbid conditions and
enhance their diagnosis and treatment, more research in
dementia patients focusing on under-diagnosis as well as
on their health care-seeking behaviour is needed. In this
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tudes towards comorbidity seems to be desirable.
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